CMS Is Proposing to Eliminate the NTAP Alternative Pathway. Here's What MedTech Innovators Need to Know.

Buried in the 1,900-plus pages of the FY2027 IPPS Proposed Rule (published April 14, 2026) is a policy shift that every MedTech innovator with a Breakthrough Device designation should stop and read carefully. CMS is proposing to eliminate the Alternative Pathway for New Technology Add-on Payments (NTAP), the reimbursement on-ramp that has allowed FDA Breakthrough Device-designated technologies to qualify for supplemental Medicare inpatient payments without independently demonstrating substantial clinical improvement to CMS's satisfaction. The agency is proposing a parallel elimination for OPPS device pass-through payments as well.

This pathway has been a cornerstone of MedTech reimbursement strategy for nearly six years. To put the stakes in concrete terms: for FY2027 alone, CMS received 32 alternative pathway applications, more than double the 15 submitted under the traditional pathway, representing an estimated $589 million in proposed add-on payments [FY2027 IPPS Proposed Rule, Section II.E.7]. The proposed repeal would not affect those pending FY2027 applications, but it would fundamentally reshape reimbursement strategy for every company planning an NTAP application in FY2028 and beyond.

What the Alternative Pathway Was and Why It Mattered

To understand what's at stake, it helps to revisit why the Alternative Pathway was created in the first place.

Under the traditional NTAP framework, a technology must satisfy three criteria to qualify for supplemental Medicare inpatient payments: (1) it must be new enough that its costs are not yet adequately reflected in existing MS-DRG weights; (2) its costs must be inadequately covered by the applicable DRG payment; and (3) it must represent a substantial clinical improvement over existing alternatives.

That third criterion, the Substantial Clinical Improvement (SCI) standard, has historically been the most difficult to meet, particularly early in a product's commercial life when real-world outcomes data is limited.

CMS addressed this tension when it created the Alternative Pathway in the FY2020 IPPS Final Rule for "certain transformative new devices," and then expanded it in the FY2021 IPPS Final Rule to include qualifying antimicrobial products [FY2027 IPPS Proposed Rule, Section II.E.7]. The core logic was elegant: if FDA had already subjected a technology to rigorous review under its Breakthrough Device program, a designation that itself requires demonstration of more effective treatment or diagnosis of a serious condition, then CMS would treat that FDA determination as a functional proxy for its own clinical evidence review. Companies did not need to separately satisfy CMS's "not substantially similar" and "substantial clinical improvement" requirements.

The pathway applied to medical devices that held FDA Breakthrough Device designation and had received FDA marketing authorization for the indication covered by that designation. It also extended to qualifying infectious disease products (QIDPs and LPAD-approved antimicrobials), and was mirrored in the CY2020 OPPS Final Rule for OPPS device pass-through payments.

For MedTech companies, this alignment between FDA and CMS review was enormously valuable. It reduced duplicative evidentiary burden, compressed timelines, and gave hospitals a financial cushion to adopt new technologies at a stage when clinical data, while promising, was still maturing.

How Dominant the Pathway Had Become

The volume of FY2027 applications tells its own story about how central the Alternative Pathway had become to MedTech reimbursement strategy.

CMS received 32 alternative pathway applications for FY2027, compared to just 15 under the traditional pathway [FY2027 IPPS Proposed Rule, Section II.E.7]. Of those 32 alternative pathway applicants, 7 were found ineligible and 3 withdrew, leaving 22 applications proposed for approval. The estimated cost of those approvals, if finalized, is approximately $589 million in FY2027 NTAP payments alone [FY2027 IPPS Proposed Rule, Section II.E.7].

That ratio, more than two alternative pathway applications for every one traditional application, reflects a structural shift in how the MedTech industry approached NTAP. The Alternative Pathway had effectively become the default route for Breakthrough Device-designated technologies. Its proposed elimination is not a technical adjustment; it is a restructuring of the NTAP landscape.

Why CMS Is Proposing to Eliminate It

CMS has been direct about its reasoning, and it's worth quoting the agency's language carefully because it signals how the agency now views the relationship between FDA designation and Medicare reimbursement policy.

In the proposed rule, CMS states that "as we have gained experience, we have concerns with the limited evaluation process for alternative pathway applications... we believe it is in the best interest of Medicare patients to refine our approach, to ensure that all new technologies approved for new technology add-on payment have demonstrated that the technology is not substantially similar to existing technologies and represents an advance that substantially improves, relative to technologies previously available, the diagnosis or treatment of Medicare beneficiaries" [FY2027 IPPS Proposed Rule, Section II.E.7].

The agency also frames this as a matter of consistency and program integrity: "holding all applicants to the same standards by requiring all applicants to demonstrate that their technologies meet the same criteria would ensure that all applications undergo the same review process by CMS" [FY2027 IPPS Proposed Rule, Section II.E.7].

There is an almost self-referential quality to the agency's rationale. When CMS first created the pathway, it acknowledged that it would be "prudent to gain experience" before expanding or modifying the program. Having now gained that experience, and having watched alternative pathway applications far outpace traditional ones, CMS has apparently concluded that the pathway creates more risk of approving payments for technologies that have not yet demonstrated Medicare-relevant clinical value than it does good in reducing regulatory friction.

Crucially, CMS is not suggesting that FDA Breakthrough Device designation lacks value. It is drawing a clear jurisdictional line: FDA's designation process answers a different question than CMS's SCI determination, and the agency does not believe one should substitute for the other.

What Changes and When

Understanding the timeline is critical for planning purposes.

For NTAP applications, the repeal would apply to applications received for the FY2028 cycle and beyond. FY2027 applications already submitted under the Alternative Pathway will continue to be reviewed under the rules in effect when they were submitted. The proposal does not retroactively affect currently pending or approved FY2027 applications [FY2027 IPPS Proposed Rule, Section II.E.7].

For OPPS device pass-through payments, applications received on or after October 1, 2026 would be required to meet the traditional substantial clinical improvement standard under §419.66(c)(2)(i), covering cycles through CY2028 and beyond [FY2027 IPPS Proposed Rule, Section II.E.7].

The proposed rule would also eliminate the conditional approval process for antimicrobials, the mechanism that allowed products to apply for NTAP while still awaiting FDA marketing authorization, with authorization required by July 1 of the relevant fiscal year. Under the new framework, antimicrobial products would need FDA marketing authorization in hand by May 1 prior to the fiscal year, the same deadline that applies to all other applicants. As CMS notes, "this proposal would not change the time to approval, except for technologies submitted under the alternative pathway for certain antimicrobial products, for which the conditional approval process would no longer be available" [FY2027 IPPS Proposed Rule, Section II.E.7]. For developers in the antimicrobial space, where FDA review timelines and NTAP application cycles are often uncomfortably close, this is a meaningful additional constraint.

What This Means for MedTech Innovators

The strategic implications are significant and immediate for companies with FY2028 and later NTAP plans.

If the CMS repeal is finalized, Breakthrough Device Designation alone no longer provides a reimbursement shortcut. Going forward, every NTAP applicant, regardless of FDA designation status, would need to build and present a CMS-specific clinical evidence package demonstrating substantial clinical improvement. That means designing clinical programs with CMS's SCI criteria explicitly in mind, not just the endpoints required for FDA clearance or approval. The two agencies evaluate different questions, and clinical programs will need to be designed to answer both.

The three-pronged traditional test becomes universal. Companies should revisit CMS's historical guidance on what constitutes substantial clinical improvement, reductions in mortality or morbidity, decreases in hospital length of stay, improvements in patient functionality, and addressing unmet needs for patients with no alternatives, and map their clinical evidence directly to these criteria from the outset of their NTAP application development.

For antimicrobial developers, the stakes are particularly acute. The loss of conditional approval removes a critical flexibility mechanism in a therapeutic area where commercial incentives are already strained and development timelines are inherently unpredictable. Companies developing QIDPs or LPAD-designated products should model their FDA review timelines against the new May 1 deadline requirement with significant margin for uncertainty.

The OPPS pass-through pathway is equally affected. Device manufacturers who had been relying on Breakthrough Device designation to streamline the pass-through application process under OPPS will now need to satisfy the §419.66(c)(2)(i) substantial improvement requirement directly, a consideration that affects outpatient reimbursement strategy in parallel.

Most importantly: the comment period is open. This is still a proposed rule. The MedTech industry has a genuine opportunity to engage with CMS before finalization.

A Moment That Calls for Constructive Engagement

This is one of the most consequential changes to the NTAP program since the Alternative Pathway was created. Companies with pipeline devices that were planning to rely on Breakthrough Device designation for streamlined NTAP eligibility should begin reassessing their reimbursement timelines, evidence strategies, and financial projections now, not after the final rule publishes in August.

But this moment also calls for something beyond internal replanning. CMS has articulated a patient-protection rationale that deserves a thoughtful industry response — not reflexive opposition, but substantive engagement that demonstrates how the Alternative Pathway, properly structured, serves Medicare beneficiaries rather than undermining them. Industry associations, individual companies, clinical societies, and patient advocacy organizations all have standing to submit comments that make this case with data and specificity.

The pathway was built to solve a real problem: that genuinely transformative technologies should not be commercially stalled by reimbursement systems that cannot yet account for their costs. That problem has not gone away. The industry's challenge now is to make that argument persuasively and to propose solutions that give CMS the accountability mechanisms it is seeking without erecting barriers that delay patient access to the innovations that need it most.

This article is intended for informational and educational purposes only and does not constitute legal, regulatory, or reimbursement advice. Consult Nicole Coustier for guidance specific to your product and circumstances.

Summary generated with RuleIQ.ai. For more information on agentic IPPS and OPPS payment policy reporting and analysis, contact [email protected]

Do you have U.S. commercialization questions?

Whether it's how the multiple payer landscape works in the U.S., how to validate device or procedure coding, timelines associate with product uptake - we're happy to answer them.

🔗Schedule an introductory call: https://calendly.com/nicolecoustier/introductions